Skip to main content

Open Road

All trials

Alzheimer

Open Road

Leeftijd icoon
50 - 85 years (M/F)
Diagnose icoon
Dementia due to Alzheimer's disease
Duratie onderzoek
2 years
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

An open-label, multicenter, follow-up study to evaluate the safety and tolerability of long-term administration of Gantenerumab in subjects with Alzheimer’s disease.

The study is an open-label extension of the Marguerite Road and Scarlet Road study. This study is therefore only accessible to participants who participated in these studies. This study aims to evaluate both the positive effects and side effects of long-term use of gantenerumab on the subject and their memory problems. The study drug is administered by subcutaneous IV.

You and your research partner will come to the research center a maximum of about 27 times, during about 108 weeks. Each study visit lasts approximately one to three hours, depending on the procedures performed during that visit.

The research is carried out at Brain Research Center Amsterdam.

This study is commissioned by Roche.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening – Selection

There is no selection period for this research.

Treatment

Treatment takes place every 4 weeks. During these visits, various investigations and procedures take place, such as for example; physical and neurological examination, blood tests, questionnaires, memory tests, as well as ECGs and MRI scans. The duration of treatment is 104 weeks.

Follow-up

After completing the treatment phase, participants will return to the center one more time for follow-up. During these visits, questionnaires and tests will be taken for your memory, among other things. Blood tests and physical and neurological examinations will be done.

Who can participate?

  • You have a diagnosis of dementia due to Alzheimer’s disease.
  • You participated in the Marguerite or the Scarlet Road.
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and answer questions about your health and functioning.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle

All trialsAlzheimer

Together

The goal of this study is to evaluate the safety and potential effectiveness of the…

The goal of this study is to evaluate the safety and potential effectiveness of the investigational drug (bepranemab) for participants with MCI or mild Alzheimer’s Disease. The study compares the effect of the active study drug bepranemab with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). Using a placebo will help us identify improvements or side effects which are caused by the active study medication. The study drug is administered through an intravenous (IV) injection.

audience50 - 80 years

levelMild cognitive impairment (MCI) or mild Alzheimer’s disease

duration152 weeks

locationAmsterdam, Den Bosch, and Zwolle